Drugs For Malaria Market Growth Drivers by 2031
The Drugs For Malaria Market is expected to register a CAGR of 8.5% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX million by 2031.
The report is segmented by Drugs For Malaria Market By Drug Class (Quinine, Chloroquine, Proguanil, Mefloquine, Pyrimethamine, Others); Distribution (Hospital Pharmacy, Retail Pharmacy, E-Commerce, Other Distribution Channels), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Drugs For Malaria Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Drugs For Malaria Market Segmentation
Drug Class- Quinine
- Chloroquine
- Proguanil
- Mefloquine
- Pyrimethamine
- Others
- Hospital Pharmacy
- Retail Pharmacy
- E-Commerce
- Other Distribution Channels
Strategic Insights
Drugs For Malaria Market Growth Drivers- Rising Prevalence of Malaria: According to the World Health Organization (WHO), Malaria is an acute febrile illness caused by plasmodium parasites, which spread through the bites of infected female Anopheles mosquitoes. Malaria is caused by 5 parasite species in humans, and 2 of these species—Plasmodium falciparum and P. vivax—pose the greatest threat. P. falciparum is the deadliest malarial parasite, and it is the most widespread one on the African continent. P. vivax is the dominant malarial parasite in most countries outside of sub-Saharan Africa.
- Rising Cases of Malaria: According to the latest World malaria report (WMR) 2020, from the WHO, 241 million cases of malaria were reported in the world in 2020, compared to 227 million cases recorded in 2019. The number of deaths caused due to malaria stood at 0.62 million in 2020, with an annual rise of 69,000 deaths. While about two-thirds of these deaths (47,000) were due to disruptions in healthcare services during the COVID-19 pandemic, the remaining one-third of deaths (22,000) reflected a recent change in WHO’s the methodology for calculating malaria mortality (irrespective of COVID-19 disruptions)
- Rising cases in Nigeria and Congo: The WHO’s African region continues to account for a disproportionately high share of the global burden of malaria. In 2020, 95% of the global cases of malaria and 96% of deaths were reported in Africa; ~80% of the total deaths caused by malaria are reported in children below 5 years of age. Four African countries—Nigeria (31.9%), the Democratic Republic of the Congo (13.2%), the United Republic of Tanzania (4.1%), and Mozambique (3.8%)—accounted for nearly half of all malaria-related deaths reported worldwide
- Government and Private Sector’s Initiatives: Malaria awareness campaigns help enhance knowledge regarding the disease and improve behaviors promoting health, along with promoting intersectoral collaboration and social support. The WHO coordinates the Global Malaria Programme (GMP) as part of its global efforts to control and eradicate malaria. The program is led by the "Global Technical Strategy for Malaria 2016-2030" adopted by the World Health Assembly in May 2015, which was further restructured in 2021. The WHO observes 25 April as World Malaria Day every year to highlight the collective energy and commitment of the malaria communities across the world in uniting around the common objective of freeing the world from malaria.
- National Framework for Malaria Elimination: In 2016, India introduced its first National Framework for Malaria Elimination, which will be valid from 2016 through 2030. In 2019, the Indian government raised funding by more than 25% for the National Vector Borne Disease Control Programme, launched in 2003. The country has also increased its contribution as a donor to the Global Fund to fight Malaria.
- Increased Awareness and Education: In the US, efforts for controlling malaria are made primarily through the President's Malaria Initiative (PMI), overseen by the US Global Malaria Coordinator. According to the Global Health Policy, the US planned the funding of ~US$ 1 billion in FY 2022 for malaria control and research activities. The goal of the US government under the PMI Strategy 2021-2026 is to manage malaria and reduce deaths caused by it, along with a long-term aim of eradicating the disease.
- Emerging Markets: Several governments are taking initiatives to create awareness and conduct research for the development of new antimalarial drugs and vaccines. As per the WHO data, total funding for the control and elimination of malaria reached ~US$ 3 billion in 2019; the governments of endemic countries, collectively, contributed 31% (~US$ 900 million) of the total fund to create awareness and development of new vaccines. Private companies are also engaging in the fight against malaria and investing heavily in R&D activities. For instance, in 2018, Novartis invested more than US$ 100 million to enhance its research and development activities for next-generation treatments by 2023.
- Increased Market Competition: Myanmar has a national malaria control plan that is approved by the Global Fund, and it expects to eliminate the disease caused by P. falciparum by 2030. The universal healthcare coverage in the country includes access to malaria diagnosis by microscopy or rapid diagnostic tests (RDTs) and the availability of artemisinin-based combination therapies (ACTs).
- Extending Pipeline of New Drugs and Vaccines: Antimicrobial resistance threatens the public health response to many diseases, such as malaria, and the R&D of new medicines is the best strategy to overcome this challenge. With this, the antimalarial drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities in the malaria treatment market, creating lucrative opportunities for the market growth. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, is working with a large number of pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Drugs For Malaria Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Drugs For Malaria Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Antimicrobial Resistance
Middle East & Africa region is expected to witness a high growth rate in terms of CAGR after Asia Pacific region during the forecast period
Rising Prevalence of Malaria
Asia Pacific region is expected to witness the highest growth during the forecast period
The Drugs For Malaria Market is estimated to witness a CAGR of 8.5% from 2023 to 2031
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Drugs For Malaria Market - By Drug Class
1.3.2 Drugs For Malaria Market - By Distribution
1.3.3 Drugs For Malaria Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. DRUGS FOR MALARIA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. DRUGS FOR MALARIA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. DRUGS FOR MALARIA MARKET - GLOBAL MARKET ANALYSIS
6.1. DRUGS FOR MALARIA - GLOBAL MARKET OVERVIEW
6.2. DRUGS FOR MALARIA - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. DRUGS FOR MALARIA MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. QUININE
7.3.1. Overview
7.3.2. Quinine Market Forecast and Analysis
7.4. CHLOROQUINE
7.4.1. Overview
7.4.2. Chloroquine Market Forecast and Analysis
7.5. PROGUANIL
7.5.1. Overview
7.5.2. Proguanil Market Forecast and Analysis
7.6. MEFLOQUINE
7.6.1. Overview
7.6.2. Mefloquine Market Forecast and Analysis
7.7. PYRIMETHAMINE
7.7.1. Overview
7.7.2. Pyrimethamine Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. DRUGS FOR MALARIA MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION
8.1. OVERVIEW
8.2. DISTRIBUTION MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACY
8.3.1. Overview
8.3.2. Hospital Pharmacy Market Forecast and Analysis
8.4. RETAIL PHARMACY
8.4.1. Overview
8.4.2. Retail Pharmacy Market Forecast and Analysis
8.5. E-COMMERCE
8.5.1. Overview
8.5.2. E-Commerce Market Forecast and Analysis
8.6. OTHER DISTRIBUTION CHANNELS
8.6.1. Overview
8.6.2. Other Distribution Channels Market Forecast and Analysis
9. DRUGS FOR MALARIA MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Drugs For Malaria Market Overview
9.1.2 North America Drugs For Malaria Market Forecasts and Analysis
9.1.3 North America Drugs For Malaria Market Forecasts and Analysis - By Drug Class
9.1.4 North America Drugs For Malaria Market Forecasts and Analysis - By Distribution
9.1.5 North America Drugs For Malaria Market Forecasts and Analysis - By Countries
9.1.5.1 United States Drugs For Malaria Market
9.1.5.1.1 United States Drugs For Malaria Market by Drug Class
9.1.5.1.2 United States Drugs For Malaria Market by Distribution
9.1.5.2 Canada Drugs For Malaria Market
9.1.5.2.1 Canada Drugs For Malaria Market by Drug Class
9.1.5.2.2 Canada Drugs For Malaria Market by Distribution
9.1.5.3 Mexico Drugs For Malaria Market
9.1.5.3.1 Mexico Drugs For Malaria Market by Drug Class
9.1.5.3.2 Mexico Drugs For Malaria Market by Distribution
9.2. EUROPE
9.2.1 Europe Drugs For Malaria Market Overview
9.2.2 Europe Drugs For Malaria Market Forecasts and Analysis
9.2.3 Europe Drugs For Malaria Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Drugs For Malaria Market Forecasts and Analysis - By Distribution
9.2.5 Europe Drugs For Malaria Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Drugs For Malaria Market
9.2.5.1.1 Germany Drugs For Malaria Market by Drug Class
9.2.5.1.2 Germany Drugs For Malaria Market by Distribution
9.2.5.2 France Drugs For Malaria Market
9.2.5.2.1 France Drugs For Malaria Market by Drug Class
9.2.5.2.2 France Drugs For Malaria Market by Distribution
9.2.5.3 Italy Drugs For Malaria Market
9.2.5.3.1 Italy Drugs For Malaria Market by Drug Class
9.2.5.3.2 Italy Drugs For Malaria Market by Distribution
9.2.5.4 Spain Drugs For Malaria Market
9.2.5.4.1 Spain Drugs For Malaria Market by Drug Class
9.2.5.4.2 Spain Drugs For Malaria Market by Distribution
9.2.5.5 United Kingdom Drugs For Malaria Market
9.2.5.5.1 United Kingdom Drugs For Malaria Market by Drug Class
9.2.5.5.2 United Kingdom Drugs For Malaria Market by Distribution
9.2.5.6 Rest of Europe Drugs For Malaria Market
9.2.5.6.1 Rest of Europe Drugs For Malaria Market by Drug Class
9.2.5.6.2 Rest of Europe Drugs For Malaria Market by Distribution
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Drugs For Malaria Market Overview
9.3.2 Asia-Pacific Drugs For Malaria Market Forecasts and Analysis
9.3.3 Asia-Pacific Drugs For Malaria Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Drugs For Malaria Market Forecasts and Analysis - By Distribution
9.3.5 Asia-Pacific Drugs For Malaria Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Drugs For Malaria Market
9.3.5.1.1 Australia Drugs For Malaria Market by Drug Class
9.3.5.1.2 Australia Drugs For Malaria Market by Distribution
9.3.5.2 China Drugs For Malaria Market
9.3.5.2.1 China Drugs For Malaria Market by Drug Class
9.3.5.2.2 China Drugs For Malaria Market by Distribution
9.3.5.3 India Drugs For Malaria Market
9.3.5.3.1 India Drugs For Malaria Market by Drug Class
9.3.5.3.2 India Drugs For Malaria Market by Distribution
9.3.5.4 Japan Drugs For Malaria Market
9.3.5.4.1 Japan Drugs For Malaria Market by Drug Class
9.3.5.4.2 Japan Drugs For Malaria Market by Distribution
9.3.5.5 South Korea Drugs For Malaria Market
9.3.5.5.1 South Korea Drugs For Malaria Market by Drug Class
9.3.5.5.2 South Korea Drugs For Malaria Market by Distribution
9.3.5.6 Rest of Asia-Pacific Drugs For Malaria Market
9.3.5.6.1 Rest of Asia-Pacific Drugs For Malaria Market by Drug Class
9.3.5.6.2 Rest of Asia-Pacific Drugs For Malaria Market by Distribution
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Drugs For Malaria Market Overview
9.4.2 Middle East and Africa Drugs For Malaria Market Forecasts and Analysis
9.4.3 Middle East and Africa Drugs For Malaria Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Drugs For Malaria Market Forecasts and Analysis - By Distribution
9.4.5 Middle East and Africa Drugs For Malaria Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Drugs For Malaria Market
9.4.5.1.1 South Africa Drugs For Malaria Market by Drug Class
9.4.5.1.2 South Africa Drugs For Malaria Market by Distribution
9.4.5.2 Saudi Arabia Drugs For Malaria Market
9.4.5.2.1 Saudi Arabia Drugs For Malaria Market by Drug Class
9.4.5.2.2 Saudi Arabia Drugs For Malaria Market by Distribution
9.4.5.3 U.A.E Drugs For Malaria Market
9.4.5.3.1 U.A.E Drugs For Malaria Market by Drug Class
9.4.5.3.2 U.A.E Drugs For Malaria Market by Distribution
9.4.5.4 Rest of Middle East and Africa Drugs For Malaria Market
9.4.5.4.1 Rest of Middle East and Africa Drugs For Malaria Market by Drug Class
9.4.5.4.2 Rest of Middle East and Africa Drugs For Malaria Market by Distribution
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Drugs For Malaria Market Overview
9.5.2 South and Central America Drugs For Malaria Market Forecasts and Analysis
9.5.3 South and Central America Drugs For Malaria Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Drugs For Malaria Market Forecasts and Analysis - By Distribution
9.5.5 South and Central America Drugs For Malaria Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Drugs For Malaria Market
9.5.5.1.1 Brazil Drugs For Malaria Market by Drug Class
9.5.5.1.2 Brazil Drugs For Malaria Market by Distribution
9.5.5.2 Argentina Drugs For Malaria Market
9.5.5.2.1 Argentina Drugs For Malaria Market by Drug Class
9.5.5.2.2 Argentina Drugs For Malaria Market by Distribution
9.5.5.3 Rest of South and Central America Drugs For Malaria Market
9.5.5.3.1 Rest of South and Central America Drugs For Malaria Market by Drug Class
9.5.5.3.2 Rest of South and Central America Drugs For Malaria Market by Distribution
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. DRUGS FOR MALARIA MARKET, KEY COMPANY PROFILES
11.1. ALVIZIA HEALTHCARE PVT. LTD.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BAYER AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. F. HOFFMANN-LA ROCHE LTD
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. GLAXOSMITHKLINE PLC
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. IPCA LABORATORIES LTD.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. MERCK AND CO., INC
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. NOVARTIS AG
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. ZYDUS CADILA.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1.Alvizia Healthcare Pvt. Ltd.
2.Bayer AG
3.F. Hoffmann-La Roche Ltd
4.GlaxoSmithKline Plc
5.Ipca Laboratories Ltd.
6.Merck and Co., Inc
7.Novartis AG
8.Pfizer Inc.
9.Sun Pharmaceutical Industries Ltd.
10.Zydus Cadila.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For